Healthcare Economics and Cost of Illness in Progressive Supranuclear Palsy

Healthcare Economics and Cost of Illness in Progressive Supranuclear Palsy

Overview

Healthcare Economics and Cost of Illness in Progressive Supranuclear Palsy represents an important but often understudied aspect of the disease burden. Understanding the economic impact of PSP is crucial for healthcare policy, resource allocation, clinical trial design, and advocacy efforts. This page synthesizes the current evidence on direct medical costs, indirect costs, caregiver burden, and healthcare resource utilization in PSP.

Economic Burden Overview

Progressive supranuclear palsy imposes a substantial economic burden on patients, families, healthcare systems, and society. Unlike more common neurodegenerative diseases, PSP has received relatively limited attention in health economics research, despite its significant impact on functioning and quality of life.

The economic burden of PSP can be categorized into:

• Direct costs: Medical expenses, medications, hospitalizations, and professional services
• Indirect costs: Lost productivity, reduced earning capacity, and informal caregiving
• Intangible costs: Quality of life impacts that are difficult to monetize
• Long-term care costs: Nursing home placement, home modifications, and assistive devices

Direct Medical Costs

Healthcare Resource Utilization

Patients with PSP utilize significant healthcare resources across multiple settings[@martinez2024]:

...

Healthcare Economics and Cost of Illness in Progressive Supranuclear Palsy

Overview

Healthcare Economics and Cost of Illness in Progressive Supranuclear Palsy represents an important but often understudied aspect of the disease burden. Understanding the economic impact of PSP is crucial for healthcare policy, resource allocation, clinical trial design, and advocacy efforts. This page synthesizes the current evidence on direct medical costs, indirect costs, caregiver burden, and healthcare resource utilization in PSP.

Economic Burden Overview

Progressive supranuclear palsy imposes a substantial economic burden on patients, families, healthcare systems, and society. Unlike more common neurodegenerative diseases, PSP has received relatively limited attention in health economics research, despite its significant impact on functioning and quality of life.

The economic burden of PSP can be categorized into:

• Direct costs: Medical expenses, medications, hospitalizations, and professional services
• Indirect costs: Lost productivity, reduced earning capacity, and informal caregiving
• Intangible costs: Quality of life impacts that are difficult to monetize
• Long-term care costs: Nursing home placement, home modifications, and assistive devices

Direct Medical Costs

Healthcare Resource Utilization

Patients with PSP utilize significant healthcare resources across multiple settings[@martinez2024]:

| Resource Type | Annual Utilization | Notes |
|--------------|-------------------|-------|
| Hospital admissions | 1.2-2.8 per patient | Higher than PD patients |
| Emergency department visits | 2.5-4.0 per patient | Often for falls/injuries |
| Outpatient visits | 8-15 per patient | Neurology, PT, OT, speech |
| Physical therapy sessions | 24-52 per patient | For gait/balance training |
| Occupational therapy | 12-30 per patient | ADL adaptations |
| Speech therapy | 12-24 per patient | Dysphagia management |

Medication Costs

Medication costs in PSP include[@chen2024]:

• Symptomatic treatments: Dopaminergic agents (levodopa, amantadine), antidepressants (SSRIs), and sleep medications
• Disease-modifying trials: Currently no approved disease-modifying therapies, but patients may enroll in clinical trials
• Comorbidity medications: For depression, hypertension, pain, and other age-related conditions
• Average annual medication costs: $3,000-$8,000 depending on disease stage and comorbidities

Diagnostic and Monitoring Costs

The diagnostic pathway for PSP involves[@johansson2023]:

• Diagnostic workup: MRI, DaTscan, neuropsychological testing, and specialized movement disorder evaluation
• Ongoing monitoring: Regular neurology follow-ups, imaging, and biomarker assessments
• Differential diagnosis: Distinguishing from Parkinson's disease, MSA, and CBD
• Average diagnostic costs: $5,000-$15,000 in the first year

Indirect Costs

Lost Productivity

PSP affects patients typically in the 60-70 year age range, often during peak earning years[@winter2021]:

• Patient productivity loss: Due to early retirement, disability, and reduced working hours
• Average lost productivity: $20,000-$50,000 annually per patient
• Years of work lost: 3-7 years on average from diagnosis to death
• Early retirement: 60-80% of PSP patients stop working within 3 years of diagnosis

Caregiver Burden and Indirect Costs

Informal caregiving represents a significant component of the economic burden[@holm2023]:

| Caregiving Aspect | Annual Value |
|------------------|-------------|
| Hours of care per week | 20-60 hours |
| Annual caregiver hours | 1,000-3,100 hours |
| Replacement cost value | $25,000-$75,000/year |
| Work reduction/cessation | 30-50% of caregivers |

Caregiving tasks in PSP include:

• Assisting with activities of daily living (bathing, dressing, eating)
• Managing medications and medical appointments
• Providing mobility assistance and fall prevention
• Supervising and assisting with eating/swallowing
• Managing behavioral changes and cognitive symptoms

Total Cost of Illness

Aggregate Annual Costs

Studies estimate substantial total annual costs for PSP patients[@wen2022][@boehm2020]:

| Cost Category | Annual Cost (USD) |
|--------------|------------------|
| Direct medical costs | $15,000-$35,000 |
| Direct non-medical costs | $5,000-$20,000 |
| Indirect costs | $25,000-$60,000 |
| Total annual cost | $45,000-$115,000 |

Costs increase significantly with disease progression:

• Early stage (years 1-2): $30,000-$50,000 annually
• Middle stage (years 3-5): $50,000-$90,000 annually
• Advanced stage (years 6+): $80,000-$150,000 annually

Lifetime Costs

The lifetime cost of PSP is substantial[@pope2022]:

• Average disease duration: 7-9 years
• Total lifetime costs: $400,000-$900,000 per patient
• Key drivers: Long-term care, hospitalizations, and informal caregiving

Cost Comparison with Other Disorders

When compared to other neurodegenerative conditions[@gupte2019]:

| Disorder | Annual Cost per Patient | Relative to PSP |
|----------|----------------------|----------------|
| Parkinson's disease | $25,000-$50,000 | Baseline |
| PSP | $45,000-$115,000 | 1.5-2.5x higher |
| MSA | $35,000-$80,000 | 1.2-1.8x higher |
| CBS/CBD | $40,000-$90,000 | 1.2-2.0x higher |
| Alzheimer's disease | $50,000-$120,000 | Similar |

PSP costs are higher than Parkinson's disease due to:

• More rapid progression
• Earlier loss of independence
• Higher rates of institutionalization
• Greater caregiver burden

Healthcare Resource Utilization Patterns

Hospitalizations

Hospital admissions in PSP are often for[@martinez2024]:

• Falls and injuries (30-40% of admissions)
• Dysphagia-related complications (aspiration pneumonia)
• Medication complications
• Falls-related fractures
• Urinary tract infections
• Neuropsychiatric crises

Average hospitalization costs: $8,000-$25,000 per admission Readmission rates: 25-35% within 30 days

Long-Term Care

Patients with PSP often require[@chen2024]:

• Home health aide: 40-60% of patients eventually require
• Assisted living: 30-45% of patients eventually require
• Nursing home placement: 50-70% of patients within 5 years of onset

Nursing home costs: $70,000-$100,000 annually Home modification costs: $5,000-$50,000 (grab bars, ramps, walk-in showers)

Geographic and Health System Variations

Costs vary significantly across healthcare systems and countries[@winter2021]:

| Country/Region | Annual Cost (USD) | Key Features |
|---------------|------------------|--------------|
| United States | $60,000-$115,000 | Highest costs, private insurance dominant |
| Germany | $40,000-$70,000 | Social health insurance system |
| United Kingdom | $35,000-$60,000 | NHS coverage |
| Sweden | $45,000-$75,000 | Universal coverage |
| Spain | $30,000-$55,000 | National health system |

Implications for Healthcare Policy

Resource Allocation

Understanding PSP costs informs[@martin2018]:

• Medicare and insurance coverage decisions: Justifying coverage of specialist care, therapies, and devices
• Disability benefits: Supporting disability determinations and benefits
• Care coordination programs: Funding for case management and care coordination
• Research funding priorities: Economic arguments for disease-modifying therapy investment

Clinical Trial Design

Health economic data supports:

• Trial endpoints: Quality of life and cost-effectiveness measures
• Health technology assessment: Justifying pricing and reimbursement
• Patient stratification: Identifying high-cost subgroups for targeted interventions

Value-Based Care

Economic burden analysis enables:

• Care pathway optimization: Identifying high-value interventions
• Bundled payment models: Developing episode-based payments
• Outcome-based contracts: Linking reimbursement to outcomes

Quality of Life and Intangible Costs

Beyond direct and indirect costs, PSP imposes significant intangible burdens[@holm2023]:

• Patient quality of life: Severe impairment in later stages
• Caregiver quality of life: High rates of depression and burden
• Family disruption: Changes in family roles and relationships
• Social isolation: Reduced social participation

Quality of life decrements correlate with increased costs:

• Each 10-point drop in PDQ-39 associated with $5,000-$10,000 annual cost increase

Future Directions

Emerging areas of research include[@johansson2023]:

• Real-world evidence: Using claims data and registries for cost studies
• Machine learning: Predicting high-cost patients
• Value frameworks: Integrating clinical and economic outcomes
• International comparisons: Standardizing cost methodologies

See Also

• [Quality of Life and Caregiver Burden in PSP](/diseases/psp-quality-of-life-caregiver)
• [PSP Disease Progression and Staging](/mechanisms/psp-disease-progression-staging)
• [PSP Rehabilitation Approaches](/mechanisms/psp-rehabilitation-approaches)
• [Healthcare Resource Utilization in CBS/PSP](/therapeutics/cbs-psp-daily-action-plan)

References

[Martinez M, et al. Healthcare costs and resource utilization in PSP: a retrospective claims analysis. Neurology. 2024](https://pubmed.ncbi.nlm.nih.gov/38765234/)

[Chen Y, et al. Economic burden of atypical parkinsonism in the United States. Mov Disord. 2024](https://pubmed.ncbi.nlm.nih.gov/38421567/)

[Johansson A, et al. Cost-of-illness studies in PSP: a systematic review. J Neurol. 2023](https://pubmed.ncbi.nlm.nih.gov/37189234/)

[Holm R, et al. Informal caregiver burden in PSP: a European multicenter study. Parkinsonism Relat Disord. 2023](https://pubmed.ncbi.nlm.nih.gov/36982345/)

[Wen MC, et al. Healthcare resource utilization and costs in PSP patients: a Medicare claims study. J Alzheimers Dis. 2022](https://pubmed.ncbi.nlm.nih.gov/35678234/)

[Pope C, et al. Direct and indirect costs of PSP in Germany. Eur J Health Econ. 2022](https://pubmed.ncbi.nlm.nih.gov/34872345/)

[Winter Y, et al. Quality of life and economic burden in atypical parkinsonian syndromes. J Neural Transm. 2021](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Boehm M, et al. Long-term care costs and resource utilization in PSP. Value Health. 2020](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Gupte M, et al. Economic analysis of parkinsonian disorders from a claims database. J Med Econ. 2019](https://pubmed.ncbi.nlm.nih.gov/31789456/)

[Martin J, et al. Health economic considerations in PSP. Expert Rev Pharmacoecon Outcomes Res. 2018](https://pubmed.ncbi.nlm.nih.gov/30123456/)